Today: 9 June 2026
BlackBerry Stock Nears Highs as Traders Eye Government Moves
20 May 2026
2 mins read

BlackBerry Stock Nears Highs as Traders Eye Government Moves

TORONTO, May 20, 2026, 13:06 EDT

BlackBerry Ltd’s U.S.-listed shares rose on Wednesday, staying close to year highs, after the company said its AtHoc crisis-communications software renewed key U.S. government cloud-security approval.

BB shares were last up roughly 0.5% to $6.24 on the NYSE, trading between $6.10 and $6.37 for the day, with volume topping 27 million shares, according to market data. The move keeps the stock well under its 52-week high of $6.64 and well above the 52-week low near $3.12.

BlackBerry is pointing to fresh FedRAMP re-certification for its AtHoc service, which handles government and critical-infrastructure communications—areas where the company still pushes its trust angle. The company said AtHoc completed 2026 Class D High re-certification, meeting the U.S. government’s cloud security standards for federal agencies. That “High” bar is for cloud services with sensitive unclassified data that, if compromised, could seriously disrupt operations or public safety. ACCESS Newswire

Ramon Pinero, general manager at BlackBerry AtHoc, said the renewal showed the platform’s “security rigor.” Dubhe Beinhorn, senior vice president for public sector at BlackBerry Secure Communications, called compliant infrastructure “essential” because agencies are up against more complex threats. ACCESS Newswire

BlackBerry’s CFO Tim Foote and QNX President John Wall are scheduled for a near-term investor pitch. They’ll speak at the CIBC Technology & Innovation Conference in Toronto on Thursday at 9:10 a.m. ET. After that, they’re listed for a Baird event in New York on June 2.

BlackBerry isn’t trading like an old phone play now. Investors are watching QNX, its real-time OS business, as well as Secure Communications, which sells secure messaging and emergency-response software.

QNX revenue rose 20% to $78.7 million in the fourth quarter, with its royalty backlog at about $950 million, Reuters reported in April. CEO John Giamatteo told Reuters the business deals with “highly regulated, complex” systems and said the company may consider “M&A tuck-ins” to boost QNX growth. Reuters

Competitive moves look mixed. BlackBerry is pushing further on embedded systems through Nvidia. In April, QNX said it had extended collaboration with Nvidia to integrate QNX OS for Safety 8.0 with Nvidia’s IGX Thor and Halos Safety Stack, targeting robotics, medtech and industrial edge-AI setups.

BlackBerry is a niche player in security software, unlike Palo Alto Networks or CrowdStrike. Palo Alto Networks shares were up 2.6% Wednesday, CrowdStrike climbed 4.0%. BlackBerry (BB) didn’t move as much, despite its government-certification headline.

Options on BlackBerry saw some buying but traders kept a lid on bullish bets. Moderately bullish flow, with call volume ahead of puts, was flagged by TheFly via TipRanks. Implied volatility landed in the top 25% of the 12-month range and traders bought more downside protection, according to the report.

The stock might have gotten ahead of analyst targets. Benzinga had a Hold consensus and a $5.02 average price target, which is under where shares traded on Wednesday. RBC Capital stayed at Sector Perform, saying it doesn’t see the name beating peers, and warned about auto-production delays and project deferrals as risks for QNX.

BlackBerry plans to release first-quarter fiscal 2027 results on June 25, according to its investor site. Investors looking for clues on QNX demand, government communications budgets and possible buybacks or acquisitions before then will focus on Thursday’s CIBC event.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn
Previous Story

Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn

NIO Drops Ahead of Earnings With $5 EV Stock in Focus
Next Story

NIO Drops Ahead of Earnings With $5 EV Stock in Focus

Go toTop